FDA advisory panel has backed and given a green signal to Auxilium Pharmaceutical’s experimental Xiaflex therapy which cures Dupuytren’s contracture. The FDA panel has stated that the Xiaflex therapy is absolutely effective and safe and a better alternative to surgery as a treatment for a condition that affects the connective tissues in the hand. With this approval by FDA, Auxilium’s share prices have been stable for sometime as investors are waiting for what’s the next step, to make sure they have invested in the right place at the right time. This is not only a good news for Auxilium Pharmaceuticals but also ...

Yesterday, Wright Medical Group Inc. (WMGI) announced the launch of its direct Australian subsidiary subsidiary, Wright Medical Australia Pty, Ltd. The Australian Branch will manage the company’s extremity and biologics distribution for customers in Australia and New Zealand . The company also entered into an agreement with Australian company LSS Pty Ltd. LSS will distribute Wright’s reconstruction joint devices in the two countries from the fourth quarter of this year. The launch of a new subsidiary will not only enlarge Wright’s customer base but will also enable it to satisfy the needs of specific customer segments in that region by developing a wider range of products. Furthermore, the expansion will provide the global orthopaedic medical device company with enhanced control over distribution activities. The launch of the subsidiary comes close on the heels of the new product launched ...

NuVasive, Inc. (NUVA) is one of the top-performing Zacks #1 Rank companies on Wednesday with shares that have gained approximately 6.2%.

In late July, NUVA released its second-quarter report, which included better-than-expected EPS and a raised full-year guidance. Earnings estimates remain well above levels from 2 months ago.

The company is part of the Medical Products industry. The Zacks #1 Rank List includes 2 other companies from this space: Hanger Orthopedic Group, Inc. (HGR) and Micrus Endovascular Corporation (MEND).

NUVA is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. Volume today is about 413,000 shares; above the daily average of 391,000.

Earnings Estimates

The Zacks Consensus Estimate for this year is currently 26 cents per share, marking a 116% surge in the last 2 months from 12 cents per share.

...

TranS1 Inc. (TSON) announced that it expects revenue to be roughly in the range of $7.9 million to $8.0 million in the second quarter of this year, lower than its previous guidance of $8.7 million to $9.0 million but approximately 33% higher than the revenue in the year-ago quarter.   TranS1 believes that its revenue is likely to be affected by the reimbursement uncertainty surrounding its AxiaLIF procedure. The company expects to release its second quarter results on July 30, 2009, after the close.   TranS1 is engaged in designing, developing and marketing minimally invasive products that utilize its proprietary TranS1 surgical approach to treat degenerative disc disease affecting the lower lumbar region of the spine.   TranS1 is badly hurt by a reimbursement uncertainty surrounding its AxiaLIF procedure. We believe expected near-term reimbursement changes would make the pre-certification and administration process time-consuming and could create some revenue ...